Literature DB >> 20583863

A short polypeptide from the herpes simplex virus type 2 ICP10 gene can induce antigen aggregation and autophagosomal degradation for enhanced immune presentation.

Xinping Fu1, Lihua Tao, Xiaoliu Zhang.   

Abstract

It has been reported that certain polypeptides derived from aggregation-prone cellular proteins can turn soluble green fluorescent protein (GFP) into aggregates. Here we report our finding that a short peptide derived from a viral gene, ICP10 of herpes simplex virus (HSV)-2, also possesses such a property. A sequence as short as 13 amino acids from the middle region of the gene can convert GFP into an aggregation-prone toxic protein once it is fused to the C terminus. Moreover, this short peptide can direct a surrogate tumor antigen into the autophagosome/lysosome degradation pathway, drastically increasing both MHC class I and class II antigen presentation. The simultaneous induction of both arms of the T cell immune response to the tumor antigen effectively protects the immunized animals from tumor challenge. Designated VIPA (i.e., viral inducer of protein aggregation), this unique viral sequence may represent an attractive candidate as a molecular adjuvant for cancer immunotherapy and for other immunologically preventable diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583863      PMCID: PMC2999574          DOI: 10.1089/hum.2010.080

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  33 in total

1.  Impairment of the ubiquitin-proteasome system by protein aggregation.

Authors:  N F Bence; R M Sampat; R R Kopito
Journal:  Science       Date:  2001-05-25       Impact factor: 47.728

2.  The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation.

Authors:  Yves Langelier; Stéphane Bergeron; Stéphane Chabaud; Julie Lippens; Claire Guilbault; A Marie-Josée Sasseville; Stéphan Denis; Dick D Mosser; Bernard Massie
Journal:  J Gen Virol       Date:  2002-11       Impact factor: 3.891

3.  The R1 subunit of herpes simplex virus ribonucleotide reductase has chaperone-like activity similar to Hsp27.

Authors:  Stéphane Chabaud; Herman Lambert; A Marie-Josée Sasseville; Hugo Lavoie; Claire Guilbault; Bernard Massie; Jacques Landry; Yves Langelier
Journal:  FEBS Lett       Date:  2003-06-19       Impact factor: 4.124

Review 4.  Autophagy in MHC class II presentation of endogenous antigens.

Authors:  Monique Gannagé; Christian Münz
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

5.  A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.

Authors:  Gerardo Casanova; Rosalia Cancela; Lourdes Alonzo; Rosa Benuto; Maria del Carmen Magana; Dennis R Hurley; Eugenia Fishbein; Claudia Lara; Teresa Gonzalez; Rebeca Ponce; Joseph W Burnett; Gary J Calton
Journal:  Cutis       Date:  2002-10

6.  Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.

Authors:  C C Smith; J Nelson; L Aurelian; M Gober; B B Goswami
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.

Authors:  Helen Y Wang; Tihui Fu; Gang Wang; Gang Zeng; Donna M Perry-Lalley; James C Yang; Nicholas P Restifo; Patrick Hwu; Rong-Fu Wang
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.

Authors:  D Perkins; E F R Pereira; M Gober; P J Yarowsky; L Aurelian
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

9.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

Review 10.  LC3 conjugation system in mammalian autophagy.

Authors:  Isei Tanida; Takashi Ueno; Eiki Kominami
Journal:  Int J Biochem Cell Biol       Date:  2004-12       Impact factor: 5.085

View more
  7 in total

Review 1.  Alternative pathways for MHC class I presentation: a new function for autophagy.

Authors:  Magali Chemali; Kerstin Radtke; Michel Desjardins; Luc English
Journal:  Cell Mol Life Sci       Date:  2011-03-10       Impact factor: 9.261

Review 2.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

Review 3.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

4.  Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines.

Authors:  Ami Patel; Jessica C Dong; Brett Trost; Jason S Richardson; Sarah Tohme; Shawn Babiuk; Anthony Kusalik; Sam K P Kung; Gary P Kobinger
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 5.  Interactions between Autophagy and DNA Viruses.

Authors:  Hai-Chang Yin; Shu-Li Shao; Xin-Jie Jiang; Peng-Yu Xie; Wan-Shu Sun; Tian-Fei Yu
Journal:  Viruses       Date:  2019-08-23       Impact factor: 5.048

Review 6.  Contribution of autophagy to antiviral immunity.

Authors:  Emma Rey-Jurado; Claudia A Riedel; Pablo A González; Susan M Bueno; Alexis M Kalergis
Journal:  FEBS Lett       Date:  2015-08-20       Impact factor: 4.124

7.  Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.

Authors:  Hoang-Thanh Le; Nya L Fraleigh; Jordan D Lewicky; Justin Boudreau; Paul Dolinar; Nitin Bhardwaj; Francisco Diaz-Mitoma; Sabine Montaut; Sarah Fallahi; Alexandrine L Martel
Journal:  Molecules       Date:  2020-03-12       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.